Funded Health Care Startups in Seattle
Disclosed round sizes in this Seattle health care list are highly skewed: Truveta’s $320M Series C (2025-01-13) is the only disclosed round above $100M, dw…
Disclosed round sizes in this Seattle health care list are highly skewed: Truveta’s $320M Series C (2025-01-13) is the only disclosed round above $100M, dwarfing the next-largest disclosed amounts such as Magnolia Medical Technologies’ $46M (2022-02-16) and DexCare’s $75M (2023-06-21). The smallest disclosed amount is Akin’s $0K (2025-04-21), while several other entries are outside the disclosed-amount comparisons entirely (Xealth on 2025-03-25 is undisclosed; Wavely Diagnostics on 2023-06-07 and Opticyte on 2023-06-06 are undisclosed). Several entries cluster in late 2023 to mid-2024: 2023-07-13 through 2024-05-21 includes Zócalo Health ($150K), Dr.Tail ($2M), One Mind for Research ($3M), Optimize.health ($18M), Abett ($12M), and Rippl Care ($23M).
Stage labeling is also mixed: Series Unknown appears in more than half of the rows shown (18 of 32), and undisclosed amounts appear in 2 of 32 rows (Xealth, Wavely Diagnostics, plus Opticyte also undisclosed amounts, totaling 3 of 32). Across stages with disclosed amounts, late-stage rounds coexist with seed raises, including DexCare’s $75M Series C (2023-06-21) alongside seed rounds like Dr.Tail’s $2M (2023-08-21) and Ora Biomedical’s $720K seed (2024-01-25). Dates span 2020-07-22 (Tasso, $17M) through 2025-10-16 (Pear Suite, $8M), with the most recent entry still in 2025.
Most recent rounds
32 shownRelated listings
Frequently asked
What’s the largest disclosed round here, and how extreme is it versus the rest of the Seattle list?
Truveta’s $320M Series C (2025-01-13) is the only disclosed round above $100M. The next-largest disclosed amounts are well below that peak (for example, DexCare $75M on 2023-06-21 and Magnolia Medical Technologies $46M on 2022-02-16).
Do any rounds cluster tightly by time in this dataset?
Yes: from 2023-12-04 (Joon, $6M) through 2024-05-21 (Abett, $12M), multiple disclosed rounds show up back-to-back (including Truveta $320M on 2025-01-13 outside that window, but Rippl Care $23M on 2024-10-02 and Abett in May 2024). Another visible cluster is mid-2023, with seed and later-stage disclosures around 2023-06-06 to 2023-10-10 (Optimize.health $18M on 2023-10-10; DexCare $75M on 2023-06-21; Key Proteo $3M on 2023-05-16).
How often are amounts missing or unlabelled, and does that affect comparisons?
Series Unknown appears in 18 of 32 rows, which limits stage-based conclusions. Separately, three rows list amounts as undisclosed (Xealth on 2025-03-25; Wavely Diagnostics on 2023-06-07; Opticyte on 2023-06-06), so they don’t participate in disclosed-size ranking.
Which stage types dominate among the rows shown?
Series Unknown is the most frequent classification at 18 of 32 rows (including Xealth 2025-03-25 and VillageReach 2024-09-18). Among named stages with disclosed amounts, the list still spans early to late: seed raises like Ora Biomedical ($720K, 2024-01-25) coexist with late-stage rounds like DexCare’s $75M Series C (2023-06-21).
Are there outliers worth flagging besides Truveta’s peak size?
Akin’s $0K (2025-04-21) is a low outlier on the disclosed side, sitting far below other small disclosed rounds such as Zócalo Health’s $150K (2023-07-13) and Nanodropper’s $1M (2021-04-19). On the high end, after Truveta’s $320M, the next tier begins below $100M, led by DexCare at $75M (2023-06-21).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.